Retrieve available abstracts of 10 articles: HTML format
Single Articles
July 2025
WANG Y, Wu Y, Jiang H, Li S, et al L-Kynurenine activates the AHR-PCSK9 pathway to mediate the lipid metabolic and
ovarian dysfunction in polycystic ovary syndrome.
Metabolism. 2025;168:156238. PubMedAbstract available
March 2025
DE MOURA DE SOUZA M, Mendes BX, Defante MLR, de Athayde de Hollanda Morais BA, et al Apolipoprotein C-III inhibitors for the treatment of hypertriglyceridemia: A
meta-analysis of randomized controlled trials.
Metabolism. 2025 Mar 10:156187. doi: 10.1016/j.metabol.2025.156187. PubMedAbstract available
November 2024
CONGUR I, Mingrone G, Guan K Targeting endoplasmic reticulum stress as a potential therapeutic strategy for
diabetic cardiomyopathy.
Metabolism. 2024 Nov 6:156062. doi: 10.1016/j.metabol.2024.156062. PubMedAbstract available
September 2024
JEONG JH, Kim YG, Han KD, Roh SY, et al Association of fatty liver index with sudden cardiac arrest in young adults.
Metabolism. 2024;158:155981. PubMedAbstract available
DANPANICHKUL P, Suparan K, Dutta P, Kaeosri C, et al Disparities in metabolic dysfunction-associated steatotic liver disease and
cardiometabolic conditions in low and lower middle-income countries: a systematic
analysis from the global burden of disease study 2019.
Metabolism. 2024;158:155958. PubMedAbstract available
July 2024
HAGVE M, Pereira SL, Walker DK, Engelen MPKJ, et al Statin treatment reduces leucine turnover, but does not affect endogenous
production of beta-hydroxy-beta-methylbutyrate (HMB).
Metabolism. 2024;156:155920. PubMedAbstract available
June 2024
EZHILARASAN D Deciphering the molecular pathways of saroglitazar: A dual PPAR alpha/gamma agonist for
managing metabolic NAFLD.
Metabolism. 2024;155:155912. PubMedAbstract available
April 2024
ZELJKOVIC A, Vekic J, Stefanovic A Obesity and dyslipidemia in early life: Impact on cardiometabolic risk.
Metabolism. 2024;156:155919. PubMedAbstract available
November 2023
ZUO F, Wang Y, Xu X, Ding R, et al CCDC92 deficiency ameliorates podocyte lipotoxicity in diabetic kidney disease.
Metabolism. 2023 Nov 10:155724. doi: 10.1016/j.metabol.2023.155724. PubMedAbstract available
July 2023
WANG YD, Wu LL, Mai YN, Wang K, et al miR-32-5p induces hepatic steatosis and hyperlipidemia by triggering de novo
lipogenesis.
Metabolism. 2023 Jul 12:155660. doi: 10.1016/j.metabol.2023.155660. PubMedAbstract available